ClinicalTrials.gg
CompletedNCT06323655Updated Mar 21, 2024

Evaluation of Next-Day Residual Effects of Tasimelteon Compared With Placebo and Active Control in Healthy Subjects

A Phase 1 interventional study of Tasimelteon and Active Control Placebo in Healthy Volunteers, sponsored by Vanda Pharmaceuticals. Completed at 1 site in Canada. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-21.

Sponsored by Vanda Pharmaceuticals · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Aug 2018, 8 years 2 months ago, and no results have been posted to the registry.
  • Registered 1 year 2 months after the study started (first participant enrolled Jul 2018, registered Oct 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
21 Years to 55 Years
Sex
All
01

Study summary

The aim of this study is to investigate next-day residual effects of tasimelteon compared with placebo and active control in healthy subjects.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Vanda Pharmaceuticals is the lead sponsor of 82 studies on the registry; 17 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 22 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to provide written consent;
  • Healthy subjects with no medical, psychiatric, or current sleep disorders;
  • Men and women ages 21 - 55, inclusive;
  • Possession of a valid driver's license ≥ 3 years with reported annual mileage ≥ 3,000 km.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or recent pregnancy;
  • Subjects who are unable to read or speak English or French.
05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Tasimelteon

    single dose

    Drug: Tasimelteon · Drug: Active Control Placebo

  • Placebo comparator
    Placebo

    single dose

    Drug: Active Control Placebo · Drug: Tasimelteon Placebo

  • Active comparator
    Active Control

    single dose

    Drug: Tasimelteon Placebo · Drug: Active Control

Interventions

  • oral capsule

  • DrugActive Control Placebo

    oral capsule

  • DrugTasimelteon Placebo

    oral capsule

  • DrugActive Control

    oral capsule

06

What researchers measure

Primary outcomes

  1. Next-day effects on simulated driving performance as measured by changes in Standard Deviation of Lateral Position (SDLP)

    Time frame: Day 1 of Treatment Period 1, Treatment Period 2, and Treatment Period 3 (each Period is 1 day, separated by washout)

07

Study locations

1 site
  • Vanda Investigational Site
    Laval, Quebec, Canada
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in Aug 2018, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2019
First posted
Mar 21, 2024
StartActual
Jul 19, 2018
Primary completionActual
Aug 28, 2018
CompletionActual
Aug 28, 2018
Last update
Mar 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06323655
Responsible party
Sponsor
First posted
Mar 21, 2024
Start date
Jul 19, 2018
Primary completion
Aug 28, 2018
Completion
Aug 28, 2018
Last update
Mar 21, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tasimelteon

Start the discussion